. 2023 Dec;51(1):196-201.

doi: 10.1007/s00259-023-06439-2. Epub 2023 Sep 16.

Melanin-targeted [¹⁸F]-PFPN PET imaging may shed light for clear cell sarcoma

Xiao Zhang^{1

2

3}, Fei Kang⁴, Huaiyuan Zheng⁵, Yongkang Gai^{1

2}, Jing Wang⁴, Xiaoli Lan^{6

7

8}

Affiliations

¹ Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China.
² Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
³ Key Laboratory of Biological Targeted Therapy, the Ministry of Education, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China.
⁴ Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, No. 127 West Changle Road, Xi'an, China.
⁵ Department of Hand Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China.
⁶ Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China. xiaoli_lan@hust.edu.cn.
⁷ Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China. xiaoli_lan@hust.edu.cn.
⁸ Key Laboratory of Biological Targeted Therapy, the Ministry of Education, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China. xiaoli_lan@hust.edu.cn.

PMID: 37714979
DOI: 10.1007/s00259-023-06439-2

Melanin-targeted [¹⁸F]-PFPN PET imaging may shed light for clear cell sarcoma

Xiao Zhang et al. Eur J Nucl Med Mol Imaging. 2023 Dec.

. 2023 Dec;51(1):196-201.

doi: 10.1007/s00259-023-06439-2. Epub 2023 Sep 16.

Authors

Xiao Zhang^{1

2

3}, Fei Kang⁴, Huaiyuan Zheng⁵, Yongkang Gai^{1

2}, Jing Wang⁴, Xiaoli Lan^{6

7

8}

Affiliations

¹ Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China.
² Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
³ Key Laboratory of Biological Targeted Therapy, the Ministry of Education, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China.
⁴ Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, No. 127 West Changle Road, Xi'an, China.
⁵ Department of Hand Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China.
⁶ Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China. xiaoli_lan@hust.edu.cn.
⁷ Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China. xiaoli_lan@hust.edu.cn.
⁸ Key Laboratory of Biological Targeted Therapy, the Ministry of Education, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China. xiaoli_lan@hust.edu.cn.

PMID: 37714979
DOI: 10.1007/s00259-023-06439-2

Abstract

Purpose: Intracytoplasmic melanin pigment is a characteristic of clear cell sarcoma (CCS), which is a particularly deadly type of soft-tissue sarcoma. [¹⁸F]-N-(2-(diethylamino)ethyl)-5-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)picolinamide ([¹⁸F]-PFPN) is a positron emission tomography (PET) probe characterized by high melanin affinity. Therefore, this study aimed to investigate the feasibility of melanin-targeted [¹⁸F]-PFPN PET in patients with CCS.

Methods: This prospective single-centre study recruited patients with pathologically confirmed CCS. [¹⁸F]-FDG PET/computed tomography and [¹⁸F]-PFPN PET/magnetic resonance imaging scans were performed within 1 week of each other. The lesion numbers and [¹⁸F]-FDG and [¹⁸F]-PFPN PET parameters (maximum standardized uptake value [SUVmax], mean standardized uptake value [SUVmean], metabolic/melanotic tumour volume [MTV/MLTV], and total lesion glycolysis/melanin [TLG/TLM]) were collected.

Results: Three patients with CCS were recruited and received PET imaging. A total of 56 lesions were detected on [¹⁸F]-PFPN PET, including primary tumour and distant metastases. Identical lesions were not detected on [¹⁸F]-PFPN and [¹⁸F]-FDG PET. Twelve lesions (12/39, 30.77%) on [¹⁸F]-FDG imaging were missed on [¹⁸F]-PFPN, and 20 lesions (20/47, 42.55%) on [¹⁸F]-PFPN imaging were missed on [¹⁸F]-FDG. In quantitative analysis, the [¹⁸F]-FDG SUVmean (4.60 ± 3.24) was higher than the [¹⁸F]-PFPN SUVmean (3.0 ± 2.63) in all lesions (P = 0.01). No significant correlations were found between the SUVmax, SUVmean, MLTV/MTV, and TLM/TLG values of [¹⁸F]-PFPN and [¹⁸F]-FDG (P > 0.05).

Conclusion: Melanin-targeted [¹⁸F]-PFPN PET imaging is feasible for the diagnosis of CCS. Different imaging features were displayed on [¹⁸F]-PFPN and [¹⁸F]-FDG PET imaging, demonstrating the complementary role of the tracers. Combined use of the two imaging modalities would be preferred in patients with CCS.

Clinical trial registration: NCT05963035.

Keywords: Clear cell sarcoma; Melanin; PET/MRI; [18F]-FDG; [18F]-PFPN.

PubMed Disclaimer

Cited by

Poor Diagnostic Performance of the Melanin-Binding Tracer [18 F]MEL050 in Human Melanoma Indicates Biological Heterogeneity.
Ware RE, Kee D, Roselt P, Greguric I, Katsifis A, Bourdier T, Noonan W, Murray W, Mitchell C, Downes M, Shackleton M, McArthur GA, Hicks RJ. Ware RE, et al. Mol Imaging Biol. 2025 Jun 19. doi: 10.1007/s11307-025-02025-0. Online ahead of print. Mol Imaging Biol. 2025. PMID: 40537707
Head-to-head evaluation of [¹⁸F]FDG PET/CT and [⁶⁸Ga]Ga-HX01 PET/MR in sarcoma patients.
Zhang X, Gai Y, Ye T, Fan L, Xiu L, Ruan W, Hu F, Chen J, Lan X. Zhang X, et al. Eur J Nucl Med Mol Imaging. 2025 Jul;52(8):2898-2905. doi: 10.1007/s00259-025-07130-4. Epub 2025 Feb 20. Eur J Nucl Med Mol Imaging. 2025. PMID: 39976700 Clinical Trial.

References

1. TahiriElousrouti L, Hammas N, Elmernissi FZ, Elfatemi H, Chbani L. Clear-cell sarcoma with an unusual presentation mimicking metastatic melanoma. Cureus. 2022;14(11):e32010. https://doi.org/10.7759/cureus.32010 . - DOI
1. Panza E, Ozenberger BB, Straessler KM, Barrott JJ, Li L, Wang Y, et al. The clear cell sarcoma functional genomic landscape. J Clin Invest. 2021;131(15):e146301. https://doi.org/10.1172/jci146301 . - DOI - PubMed - PMC
1. WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours, 5th ed. Vol. 3). https://publications.Iarc.fr/588 . Accessed 1 Aug 2023.
1. Obiorah IE, Brenholz P, Özdemirli M. Primary clear cell sarcoma of the dermis mimicking malignant melanoma. Balkan Med J. 2018;35(2):203–7. https://doi.org/10.4274/balkanmedj.2017.0796 . - DOI - PubMed - PMC
1. Meis-Kindblom JM. Clear cell sarcoma of tendons and aponeuroses: a historical perspective and tribute to the man behind the entity. Adv Anat Pathol. 2006;13(6):286–92. https://doi.org/10.1097/01.pap.0000213052.92435.1f . - DOI - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

Grants and funding

LinkOut - more resources

Full Text Sources
- Springer
Medical
- ClinicalTrials.gov

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Melanin-targeted [¹⁸F]-PFPN PET imaging may shed light for clear cell sarcoma

Affiliations

Melanin-targeted [¹⁸F]-PFPN PET imaging may shed light for clear cell sarcoma

Authors

Affiliations

Abstract

Similar articles

Cited by

References

MeSH terms

Substances

Associated data

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Abstract

Similar articles

Cited by

References

MeSH terms

Substances

Associated data

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical